Massachusetts-based startup EIP Pharma has presented data on its sole candidate neflamapimod at AAIC 2017, the Alzheimer’s Association International Conference, underway in London.
In an oral presentation, the company provided further analyses of the episodic memory findings previously released from two Phase IIa clinical studies.
Discovered by Vertex Pharmaceuticals (Nasdaq: VRTX) and in-licensed by the company in 2014, neflamapimod is being investigated in patients with early-stage Alzheimer's disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze